Expedia Inc. diskutieren
Expedia Inc.
WKN: A1JRLJ / Symbol: EXPE / Name: Expedia / Aktie / Software & Informationsdienstleistungen / Large Cap /
243,90 €
0,29 %
Expedia Group, Inc. (NASDAQ: EXPE) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $200.00 price target on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was upgraded by analysts at HSBC Holdings plc from a "hold" rating to a "buy" rating. They now have a $215.00 price target on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $235.00 price target on the stock, up previously from $220.00.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at Oppenheimer Holdings Inc. from $210.00 to $235.00. They now have an "outperform" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was upgraded by analysts at Hsbc Global Res from a "hold" rating to a "strong-buy" rating.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $235.00 to $230.00. They now have an "outperform" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was downgraded by analysts at Piper Sandler from a "neutral" rating to an "underweight" rating. They now have a $135.00 price target on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at Bank of America Co. from $205.00 to $211.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target lowered by analysts at Benchmark Co. from $225.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $230.00 to $210.00. They now have an "outperform" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $219.00 to $183.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its "buy" rating re-affirmed by analysts at Benchmark Co..
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at Piper Sandler from $135.00 to $190.00. They now have an "underweight" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at Bank of America Corporation from $211.00 to $240.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at B. Riley from $222.00 to $260.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its "buy" rating re-affirmed by analysts at Citigroup Inc..
Ratings data for EXPE provided by MarketBeat
Expedia Group, Inc. (NASDAQ: EXPE) had its price target raised by analysts at Benchmark Co. from $215.00 to $265.00. They now have a "buy" rating on the stock.
Ratings data for EXPE provided by MarketBeat
Neueste Beiträge
SVB_Leerink_LLC in Ultragenyx Pharmaceutical Inc. diskutieren